
ZOETIS INC
ZTSNYSETrading Snapshot
- Day Range
- $392.35 β $404.75
- 52-Week Range
- $71.45 β $160.48
- Volume
- $2.90B
- Avg Volume
- $2.86B
- Shares Outstanding
- 419.2M
- Next Earnings
- Oct 8, 2026
Fundamentals Snapshot
- Annual Revenue
- $9.47B
- Last Q Revenue
- $2.47B
- P/E Ratio
- 11.6
- P/S Ratio
- 3.2x
- EPS (TTM)
- $6.08
- Dividend Yield
- 2.92%
Why Investors Own ZTS
- βHigh-growth profile β revenue up +54.7% YoY with expanding US Equity exposure.
- βHealthy economics β 60% gross margin and 18% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About ZOETIS INC
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
Otter Score Breakdown
βAnalyst Price Target
βLatest News & Updates
ZOETIS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift ZTS price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
ZOETIS INC announces new agreement to expand its footprint
The move broadens the companyβs reach and could add incremental revenue over the next year.